These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 19428916)

  • 1. Effectiveness of two pertussis vaccines in preterm Danish children.
    Hviid A
    Vaccine; 2009 May; 27(23):3035-8. PubMed ID: 19428916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany.
    Juretzko P; von Kries R; Hermann M; Wirsing von König CH; Weil J; Giani G
    Clin Infect Dis; 2002 Jul; 35(2):162-7. PubMed ID: 12087522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark.
    Hviid A; Stellfeld M; Andersen PH; Wohlfahrt J; Melbye M
    Vaccine; 2004 Sep; 22(27-28):3530-4. PubMed ID: 15315832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children.
    Vickers D; Ross AG; Mainar-Jaime RC; Neudorf C; Shah S
    CMAJ; 2006 Nov; 175(10):1213-7. PubMed ID: 17098950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine.
    Rendi-Wagner P; Kundi M; Mikolasek A; Vécsei A; Frühwirth M; Kollaritsch H
    Vaccine; 2006 Aug; 24(33-34):5960-5. PubMed ID: 16757063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children.
    Lacombe K; Yam A; Simondon K; Pinchinat S; Simondon F
    Vaccine; 2004 Dec; 23(5):623-8. PubMed ID: 15542182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acellular pertussis vaccines pertinent issues.
    Mathew JL
    Indian Pediatr; 2008 Sep; 45(9):727-9. PubMed ID: 18820375
    [No Abstract]   [Full Text] [Related]  

  • 8. Shortcomings of pertussis vaccines: why we need a third generation vaccine.
    Poolman JT
    Expert Rev Vaccines; 2014 Oct; 13(10):1159-62. PubMed ID: 25089373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of an acellular pertussis vaccine in Japanese children during a non-epidemic period: a matched case-control study.
    Okada K; Ohashi Y; Matsuo F; Uno S; Soh M; Nishima S
    Epidemiol Infect; 2009 Jan; 137(1):124-30. PubMed ID: 18474125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of pre-school booster vaccination of 4--6-year-old children on pertussis in 0--1-year-old children.
    Hviid A; Stellfeld M; Wohlfahrt J; Andersen PH; Melbye M
    Vaccine; 2006 Feb; 24(9):1401-7. PubMed ID: 16207504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children.
    Hallander HO; Ljungman M; Storsaeter J; Gustafsson L
    APMIS; 2009 Nov; 117(11):797-807. PubMed ID: 19845530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada.
    Bettinger JA; Halperin SA; De Serres G; Scheifele DW; Tam T
    Pediatr Infect Dis J; 2007 Jan; 26(1):31-5. PubMed ID: 17195702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost of epidemiological transition: a study of a decrease in pertussis vaccination coverage.
    Girard DZ
    Health Policy; 2005 Nov; 74(3):287-303. PubMed ID: 15951048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acellular vaccines for preventing pertussis in children.
    Bailey J
    Am Fam Physician; 2011 Sep; 84(5):504. PubMed ID: 21888301
    [No Abstract]   [Full Text] [Related]  

  • 15. WHO working group on standardisation and control of acellular pertussis vaccines--report of a meeting held on 16-17 March 2006, St. Albans, United Kingdom.
    Xing DK; Corbel MJ; Dobbelaer R; Knezevic I
    Vaccine; 2007 Apr; 25(15):2749-57. PubMed ID: 17368348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal immunisation of murine neonates using whole cell and acellular Pertussis vaccines.
    Hale C; Humphreys IR; Hussell T; Bowe F; Clare S; Pickard D; Preston A; Del Giudice G; Dougan G
    Vaccine; 2004 Sep; 22(27-28):3595-602. PubMed ID: 15315838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prevention of pertussis and high expectations concerning vaccines].
    Wysocki J
    Przegl Epidemiol; 2004; 58 Suppl 1():39-43. PubMed ID: 15807156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of adverse effects following immunization with vaccine containing whole-cell vs. acellular pertussis components.
    Zieliński A; Rosińska M
    Przegl Epidemiol; 2008; 62(3):589-96. PubMed ID: 19108523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Has the change to acellular pertussis vaccine improved or worsened pertussis control?
    Halperin SA; De Serres G
    CMAJ; 2006 Nov; 175(10):1227. PubMed ID: 17098952
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands.
    de Greeff SC; Mooi FR; Schellekens JF; de Melker HE
    Pediatr Infect Dis J; 2008 Mar; 27(3):218-23. PubMed ID: 18277916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.